Chemotherapy for a young patient with a node-positive triple negative breast cancer

Chemotherapy for a Young Patient with Triple Negative Breast Cancer

  • The best choice for chemotherapy for a young patient with a node-positive triple negative breast cancer:
    • Would be dose-dense doxorubicin and cyclophosphamide, followed by paclitaxel, each given for 4 cycles 2 weeks apart with growth factor support:
      • This regimen is supported by results of the:
        • CALGB 9741 study
    • For triple negative breast cancer and node positive disease:
      • The use of an anthracycline-containing regimen is favored compared to a non-anthracycline containing regimen
  • References:
    • Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439.
    • Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA et al. Anthracyclines in early breast cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35(23):2647-2655.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s